Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Global Zolpidem Tartrate Market 2017 - FARMAK, Bachem, Sanofi, Aarti Group, Gador

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/23/2017 | 08:52pm CEST

The report focuses on global major leading industry players with information such as company profiles, product picture and specifications, sales, market share and contact information. What's more, the Zolpidem Tartrate industry development trends and marketing channels are analyzed.

This report studies Zolpidem Tartrate in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
Sanofi
Bachem
Taj Pharmaceuticals Limited.
Sun Pharmaceutical Industries Ltd.
FARMAK
Aarti Group
Gador

By types, the market can be split into
Zolpidem Tartrate Tablet
Zolpidem Tartrate Injection

By Application, the market can be split into
Hospital
Clinic
Other
 
Download Free Sample Report @ https://www.fiormarkets.com/report-detail/63326/request-sample

By Regions, this report covers (we can add the regions/countries as you want)
North America
China
Europe
Southeast Asia
Japan
India

If you have any special requirements, please let us know and we will offer you the report as you want.

 

© Copyright iCrowdNewswire LLC 2017., source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
06/23 Global Zolpidem Tartrate Market 2017 - FARMAK, Bachem, Sanofi, Aarti Group, G..
06/22 NEW TYPE 2 DIABETES FINDINGS FROM SA : Post-GWAs strategies for...
06/21 EU COURT : Vaccines can be blamed for illnesses without proof
06/21 SANOFI : EFPIA Appoints New President and Vice Presidents
06/19 SANOFI : Disclosure of trading in own shares
06/19 ARTEMISININ DERIVATIVES MARKET : Sanofi, KPC Pharmaceuticals, Guangxi Xiancaotan..
06/17 SANOFI : outlines 600m biologics manufacturing investment plan
06/16 SANOFI : Launches 'Action 2017', Worldwide Employee Stock Purchase Plan
06/16 SANOFI : Launches "Action 2017", a Worldwide Employee Stock Purchase Plan
06/16 Global Zika Virus Market 2017- Bharat Biotech, Inovio Pharmaceuticals and Gen..
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/21 AMICUS THERAPEUTICS : Elucidating The Bullish And Bearish Claims
06/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 19, 2017
06/18 SANOFI : A Good Bet On Pharma
06/15 PAREXEL teams up with Sanofi to advance the use of wearable devices to collec..
06/14 Sanofi all in with biologics production - Reuters
Advertisement
Financials (€)
Sales 2017 36 766 M
EBIT 2017 9 472 M
Net income 2017 7 964 M
Debt 2017 4 336 M
Yield 2017 3,49%
P/E ratio 2017 13,97
P/E ratio 2018 18,12
EV / Sales 2017 3,13x
EV / Sales 2018 3,00x
Capitalization 110 757 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 85,6 €
Spread / Average Target -2,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI14.27%123 860
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
More Results